HER3/CYLD axis mediates ovarian cancer cell resistance to chemotherapy via upregulation of ABCB1

Ye Zhang,Jian-Ge Qiu,Xiao-Yu Jia,Wei Wang,Wen-Jing Liu,Chen Ding,Ling-Zhi Liu,Lin Wang,Bing-Hua Jiang

DOI: https://doi.org/10.21203/rs.3.rs-1756290/v1

2022-01-01

Abstract:Abstract Background: Ovarian cancer (OC) is the most pathogenic gynecological malignant tumor in the world. Due to the difficulty of early diagnosis, most of patients developed chemo-resistance and recurrence during/after the chemotherapy. Cylindromatosis (CYLD) is one member of lysine 63 deubiquitinases, and the regulatory mechanism of CYLD in mediating cisplatin (DDP) resistance need to be elucidated.Methods: Database analysis indicated that CYLD was associated with tumor development and prognosis; Patient tumor samples and clinicopathological characteristics were used to study the clinical significance of CYLD. Molecular biological methods were used to verify the function of CYLD in chemo-resistance with the parental and drug resistant cell lines (A2780/ A2780-DDP, OVCAR3/OVCAR3-DDP). Then flow cytometry analysis, co-IP and ChIP analysis were conducted to identify the upstream regulators and downstream effectors of CYLD; The drug combination method was used to investigate the drug synergistic effect of cisplatin combination with ABCB1 inhibitor or HER3 inhibitor. Animal models were further used to verify the role of CYLD in cancer chemo-resistance.Results: The expression levels of CYLD were downregulated in pan-cancer, especially in ovarian cancer, leading to acceleration of tumor progression and cisplatin resistance. CYLD knockdown in the parental cells was sufficient to induce DDP resistance through inhibiting cell apoptosis and promoting the drug efflux via inducing the expression of ABCB1. HER3 expression levels were much higher in the resistant cells, and HER3 was the upstream mediator for CYLD suppression through STAT3 signaling. Moreover, overexpression of CYLD in the resistant cells was sufficient to promote sensitivity to platinum-based treatment both in vitro and in vivo. ABCB1 was a functional downstream target of CYLD to regulate tumor growth and drug resistance both in vitro and in vivo.Conclusions: In this study, the results demonstrated that higher HER3 expression rendered CYLD suppression, consequently, increased cisplatin resistance and induced poor prognosis by inhibiting cell apoptosis and promoting the drug efflux in OC. Our findings showed that HER3/CYLD/ABCB1 is a new signaling pathway to regulate tumor growth and DDP resistance, which are potential new therapeutic targets to overcome DDP resistance.